Genetic disruption or pharmacological inhibition of EZH2 enhances NK cells’ cytotoxicity against cancer cells through induction of interleukin 15 receptor, beta (IL-15Rβ), and NKG2D expressions [29]. The gene discussed is KLRK1; the disease is cancer.